Related Experiment Video
Updated: Jun 28, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor
Zeng Li1, Jin Han, Hai-Feng Chen
1College of Life Science and Biotechnology, Shanghai Jiaotong University, 800 Dongchuan Road, Shanghai 200240, China.
Chemical Biology & Drug Design
|November 18, 2008
Summary
Novel diaryltriazine analogs show potent anti-HIV activity, targeting the HIV-1 reverse transcriptase enzyme. Computational models aid in predicting the efficacy of new drug candidates for HIV treatment.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Computational Chemistry
Background:
- HIV-1 reverse transcriptase is crucial for viral replication, converting RNA to DNA.
- The Lys103Asn (K103N) mutation is frequently observed in HIV-1 reverse transcriptase.
- Developing novel inhibitors is essential to combat HIV-1, especially with resistant strains.
Purpose of the Study:
- To design and synthesize novel non-nucleoside reverse transcriptase inhibitors.
- To investigate the binding mode and interaction mechanism of diaryltriazine analogs with HIV-1 reverse transcriptase.
- To develop quantitative structure-activity relationship (QSAR) models for predicting anti-HIV activity.
Main Methods:
- Synthesis of novel diaryltriazine analogs.
- In vitro anti-HIV activity assays.
- Molecular docking and dynamics simulations to study ligand-enzyme interactions.
- Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) for QSAR modeling.
Main Results:
- Diaryltriazine analogs demonstrated potent anti-HIV activity with moderate to high selectivity.
- Computational studies suggested a consistent interaction mechanism between the analogs and HIV-1 reverse transcriptase.
- Validated QSAR models accurately predicted the activity of test compounds.
Conclusions:
- Diaryltriazine analogs are promising candidates for anti-HIV drug development.
- Computational modeling provides valuable insights for designing new inhibitors with improved efficacy.
- The developed QSAR models can guide the rational design of novel anti-HIV lead compounds, reducing experimental efforts.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
07:22A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...